Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Accustem Sciences Inc

ACUT.PK ✓ COMPLIANTFree checks used up today ☆ Track — members

USA Pink Sheets · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Micro Cap Analyst: N/A

Last Close

$0.15

▲ +0.00%

Market Cap $2.37M · Vol 14

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.37M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

92.17

Momentum

Beta

1.90

vs Market

52W High

$1.58

N/A below

52W Low

$0.12

N/A above

Volume

Avg 2.59K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

49.08%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Accustem Sciences Inc (ACUT.PK) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ACUT.PK pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.32%

-2.99%

-22.03%

-57.26%

YTD

-81.87%

-89.94%

-79.00%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-1,756,100.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-219.47% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	16.07M

Technical Indicators

50-Day SMA	$0.16
200-Day SMA	$0.33
RSI (14)	92.17
Beta	1.90
52-Week High	$1.58
52-Week Low	$0.12

Volume Today	14
Avg Daily Volume (30D)	2.59K
Relative Volume	0.01x
Volatility (10D)	37.41
Volatility (30D)	78.76
Free Float	49.08%

Analyst Consensus

N/A

Current Price $0.15

Mean Target N/A

52W Low$0.12 52W High$1.58

Current

Target

$0.12 $1.58

Current Analyst target

· 0 analysts

Identifiers

ExchangeUSA Pink Sheets

FIGIBBG015QPWJ60

ISINUS00444A1016

CountryUSA

Sub-IndustryMedical Equipment, Supplies & Distribution (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

ABT Abbott Laboratories +0.78% MDT Medtronic PLC +1.17% COR Cencora, Inc. +1.55% 7741.T HOYA CORPORATION +1.04% BDX Becton Dickinson and Co -0.80%

Company Profile

AccuStem Sciences, Inc. is a clinical-stage diagnostics company. It is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. It focuses on its proprietary genomic tests, MicroRNA Signature Classifier (MSC) for patients with lung nodules and StemPrintER for patients with early-stage breast cancer. The MSC test, a 24-micro-RNA (miRNA) assay designed to help determine whether lung nodules identified by low-dose computer tomography (LDCT) screening, are benign or malignant. StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. The assay is developed to measure the stemness of tumors, or how much a tumor behaves like stem cells, which could indicate how likely a cancer is to recur or be resistant to standard treatments, ultimately impacting how patients are managed by their multidisciplinary care team.